Introduction:

Peptides bound to cell surface MHC molecules allow the immune system to recognize intracellular pathogens and tumor-derived peptides. Each MHC allele has a distinct peptide binding motif which favours certain amino acids at particular points in a sequence. Complete Omics scientists developed and have been keeping on improving a set of methods that could capture essentially all MHC molecules and harvest the peptides presented by those MHC molecules. Through our unique neoantigen detection and quantification platform, we could help you validate neoantigens that are actually presented on the cell surface thus serving as your potential druggable targets before you investing hundreds of thousands of dollars into therapeutic method development, and provide you accurate quantification values for your neoantigen targets. Prediction methods only can predict the binding affinity, and higher affinity does not mean a valid presentation. Our Valid-NEO pipeline is completely PREDICTION-FREE, and we DIRECTLY SEE the data and let the data talk. WE DO NOT GUESS (PREDICT).

There are several milestone papers published by our team demonstrating early versions of our technique (such as MANA-SRM). Our current Valid-NEO pipeline represents a giant leap forward. Please click on the papers below for additional technical details:

Direct Detection and Quantification of Neoantigens. Cancer Immunol Res . 2019 Nov;7(11):1748-1754.

Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol . 2021 Mar 1;6(57):eabd5515.

Targeting a neoantigen derived from a common TP53 mutation. Science . 2021 Mar 5;371(6533):eabc8697.

Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.

Sample types we accept:

1, Tissue culture cell pellets

2, Tumor tissue chunk

3, Clinical Biopsy Samples (minimal 5 mg tissue)

4, Biofluids, such as plasma*, serum*, saliva, tear, etc.

*We provide High Abundance Protein Depletion Service to significantly (100-500 folds) increase the depth of your biofluid proteomics analysis by removing top abundant proteins from your samples. Read more for details​.

5, FFPE blocks

6, Customized sample types (please contact us to discuss)

Complete Omics Inc. Proudly Welcomes Proteomics Luminary Dr. Hui Zhang as Chief Scientific Officer

January 12, 2024 | BALTIMORE –  Complete Omics’ Clinical Proteomics team are thrilled to announce that Dr. Hui Zhang, a distinguished figure in the realm of proteomics, has joined the…

Read more

Securing a Brighter Future: Celebrating Our Investment from Qiming Venture Partners

November 25, 2023 | BALTIMORE –  Complete Omics management team are thrilled to announce a significant milestone for our company – a recent investment by Qiming Venture Partners. This partnership…

Read more

Complete Omics Inc. Founder Qing Wang Featured on Wharton Business School’s Official Website

July 27, 2023 | BALTIMORE –  Complete Omics is proud to announce a momentous occasion for Complete Omics Inc.: our visionary founder, Qing Wang, has been featured on the prestigious…

Read more

Some of our impacts